Literature DB >> 20338662

An R function to non-parametric and piecewise analysis of competing risks survival data.

Thomas Filleron1, Agnès Laplanche, Jean-Marie Boher, Andrew Kramar.   

Abstract

Competing risks are frequently encountered in the analysis of survival data. Different methods of analysis can be used in estimated and comparing cumulative incidence functions provided enough information is available as to the times and causes of failure. Algorithms written in R have been developed to handle this type of data. In this paper we propose an R add-on function to the cmprsk package. This function is specifically oriented towards the non-parametric analysis of competing risk data and which provides analyses of three commonly used methods all in one program. We illustrate the use of this function with two examples in oncology and compare the estimates with those provided on the cmprsk and survival package. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Mesh:

Year:  2010        PMID: 20338662     DOI: 10.1016/j.cmpb.2010.02.004

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  4 in total

1.  Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis.

Authors:  Xue Song; Yangyang Xie; Yurou Zhu; Yafang Lou
Journal:  BMC Cancer       Date:  2022-05-13       Impact factor: 4.638

2.  Competing risk analysis of cardiovascular/cerebrovascular death in T1/2 kidney cancer: a SEER database analysis.

Authors:  Xiaofei Mo; Mingge Zhou; Hui Yan; Xueqin Chen; Yuetao Wang
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

3.  The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis.

Authors:  Yangyang Xie; Danwei Du; Xue Song; Xiaowen Li; Zhongkai Ni; Hai Huang
Journal:  World J Surg Oncol       Date:  2022-04-17       Impact factor: 3.253

4.  Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Authors:  Daniel L Hertz; Kouros Owzar; Sherrie Lessans; Claudia Wing; Chen Jiang; William Kevin Kelly; Jai Patel; Susan Halabi; Yoichi Furukawa; Heather E Wheeler; Alexander B Sibley; Cameron Lassiter; Lois Weisman; Dorothy Watson; Stefanie D Krens; Flora Mulkey; Cynthia L Renn; Eric J Small; Phillip G Febbo; Ivo Shterev; Deanna L Kroetz; Paula N Friedman; John F Mahoney; Michael A Carducci; Michael J Kelley; Yusuke Nakamura; Michiaki Kubo; Susan G Dorsey; M Eileen Dolan; Michael J Morris; Mark J Ratain; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2016-05-03       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.